Immunology

Driven by Our Patients

Congress Materials

IPIC 2023 | 8–10 Nov 2023 | View Materials
PNS 2023 | 17–20 June 2023 | View Materials
EAACI 2023 | 09–11 June 2023 | View Materials
ESID 2022 | 12–15 October 2022 | View Materials
ESID 2020 | 14–17 October 2020 | View Materials

Meet Us at an Event

EAACI 2024	31 May–3 June 2024	Valencia, Spain	Details
PNS 2024	22–25 June 2024	Montreal, Canada	Details
ESID 2024	16–19 October 2024	Marseille, France	Details

Prescribing information for HAEGARDA^® and Berinert^® may vary depending on local approval in each country. Therefore, before prescribing HAEGARDA^® or Berinert^®, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SmPC) in your country.

HAEGARDA^® and Berinert^® are not available in all countries. Consult the CSL Behring Global Products List to see if HAEGARDA^® and Berinert^® are available in your country.

CSL Ltd Annual Report 2022. CSL Ltd. Published 2022. Accessed September 6, 2022. https://investors.csl.com/annualreport/2022/2/

CMD-BRN-0052
May 2023